Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Nonparametric Estimation from Incomplete Observations

1992 • 45,923 citations

Nonparametric Estimation from Incomplete Observations

1958 • 37,219 citations

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 • 5,572 citations

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

2015 • 5,267 citations

THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL

1934 • 4,169 citations

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

2018 • 3,846 citations

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 • 2,104 citations

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

2009 • 1,957 citations

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

2013 • 1,792 citations

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

2011 • 1,767 citations

Discrete Sequential Boundaries for Clinical Trials

1983 • 1,584 citations

Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma

2002 • 1,471 citations

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

2016 • 1,122 citations

Systemic Therapy for Metastatic Renal-Cell Carcinoma

2017 • 1,066 citations

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

2013 • 697 citations

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

2017 • 550 citations

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

2013 • 390 citations

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

2017 • 275 citations

Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo

2013 • 246 citations

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

2018 • 236 citations

Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

2014 • 232 citations

IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)

2018 • 193 citations

Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer

2009 • 185 citations

Kidney cancer: The next decade

2018 • 161 citations

Repeated confidence intervals for group sequential clinical trials

1984 • 148 citations

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake

2020 • 82 citations

A Comparison of the Renal Cell Carcinoma–Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy–Kidney Symptom Index (FKSI)

2009 • 41 citations

Development and Initial Validation of the NCCN/FACT Symptom Index for Advanced Kidney Cancer

2013 • 37 citations

Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer

2020 • 21 citations

Tivozanib in renal cell carcinoma: a new approach to previously treated disease

2020 • 19 citations

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

2020 • 14 citations

<p>Optimal Management of First-Line Advanced Renal Cell Carcinoma: Focus on Pembrolizumab</p>

2020 • 6 citations

First-line (1L) or second-line (2L) avelumab monotherapy in patients (pts) with advanced renal cell carcinoma (aRCC) enrolled in the phase Ib JAVELIN solid tumor trial

2018 • 2 citations